Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech Reports Favorable Review of COVID-19 Study

Accesswire June 18, 2021

Edesa Biotech to Attend BIO Digital 2021

Accesswire June 8, 2021

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Accesswire June 3, 2021

Edesa Biotech to Join Panel Discussion at Industry Event

Accesswire May 28, 2021

Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results

Accesswire May 14, 2021

Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome

Accesswire April 22, 2021

Edesa Biotech Expands Rights to Anti-Inflammatory Technology

Accesswire March 22, 2021

Edesa Biotech Reaches Enrollment Milestone in COVID Study

Accesswire March 15, 2021

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Accesswire March 9, 2021

Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares

Accesswire March 2, 2021

Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million

Accesswire February 25, 2021

Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares

Accesswire February 25, 2021

Edesa Biotech Reports Fiscal First Quarter 2021 Results

Accesswire February 16, 2021

Edesa Biotech Receives C$14 million for COVID-19 Study

Accesswire February 2, 2021

Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy

Accesswire January 26, 2021

Edesa Biotech to Join Panel Discussion at Government COVID-19 Event

Accesswire January 20, 2021

Edesa Biotech Expands COVID-19 Clinical Study to Colombia

Accesswire January 11, 2021

Edesa Biotech Issues Letter to Shareholders

Accesswire December 30, 2020

Edesa Biotech Reports Fiscal Year 2020 Results

Accesswire December 7, 2020

Edesa Biotech Enrolls First Patient in COVID-19 Study

Accesswire November 30, 2020